GRAIL, Inc.(GRAL)Earnings, Financials & Key Ratios

GRAL•NASDAQ

$68.79

Price updated Jul 7, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryMolecular and Genetic Diagnostics

AboutGRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.Show more

Revenue$147M+17.2%
EBITDA-$378M+81.4%
Net Income-$408M+79.9%
EPS (Diluted)-11.11+82.5%
Gross Margin-42.52%+31.6%
EBITDA Margin-256.72%+84.1%
Operating Margin-362.95%+79.2%
Net Margin-277.47%+82.8%
ROE-16.07%+75.6%

GRAL Price & Volume

GRAIL, Inc. (GRAL) stock price & volume — 10-year historical chart

Loading chart...

Persistent Cash Burn Challenges Clinical Scaling Trajectory

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Regulatory reimbursement dependency

Key Thesis Takeaways

GRAIL exhibits a complex investment profile characterized by 28.1% year-over-year revenue growth in 2026Q1, yet this top-line expansion remains heavily reliant on non-reimbursed clinical adoption.
The company faces significant structural headwinds, including a $10.3 billion accumulated deficit and a rapid depletion of liquid reserves that dropped to $69.3 million as of 2026Q1.
Investors should monitor the sustainability of the recent 47.9% gross margin improvement, as the firm's ongoing reliance on external capital to fund its $48.0 million quarterly R&D spend suggests continued long-term dilution risks.

Verdict Logic

the rapid depletion of cash reserves to $69.3 million in 2026Q1, combined with a $10.3 billion accumulated deficit, suggests that the company faces significant solvency risks without immediate, large-scale capital intervention.

GRAL Growth Metrics

GRAIL, Inc. (GRAL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years38.37%

TTM19.44%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM79.35%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM83%

Return on Capital

10 Years-43.45%

5 Years-41.2%

3 Years-36.43%

Last Year-18.58%

GRAL Recent Earnings

GRAIL, Inc. (GRAL) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (86%)●Beat Revenue 5/12 qtrs (71%)

Q2 2026Latest

May 5, 2026

Metric

Actual

Est

EPS

$2.29+17.1%

$2.76

Rev

$41M+4.2%

$39M

Q1 2026

Feb 19, 2026

Metric

Actual

Est

EPS

$2.44+26.7%

$3.33

Rev

$44M+0.0%

$44M

Q4 2025

Nov 12, 2025

Metric

Actual

Est

EPS

$2.46+26.8%

$3.36

Rev

$36M+4.6%

$35M

Q3 2025

Aug 12, 2025

Metric

Actual

Est

EPS

$3.18-1.3%

$3.14

Rev

$36M+4.2%

$34M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$2.29vs $2.76+17.1%	$41Mvs $39M+4.2%
Q1 2026	Feb 19, 2026	$2.44vs $3.33+26.7%	$44Mvs $44M+0.0%
Q4 2025	Nov 12, 2025	$2.46vs $3.36+26.8%	$36Mvs $35M+4.6%
Q3 2025	Aug 12, 2025	$3.18vs $3.14-1.3%	$36Mvs $34M+4.2%

Based on last 12 quarters of dataView full earnings history →

Latest GRAL News

Recent stock market news and headlines for GRAIL, Inc. (GRAL)

Globe News Wire·19h ago

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role

Bragar Eagel and Squire, P. C. Litigation Partners Brandon Walker and Melissa Fortunato Encourages Investors Who Suffered Losses In GRAIL (GRAL) To Contact Him Directly To Discuss Their Options If you purchased or acquired Grail common stock between May 13, 2025, and February 19, 2026 and would like to discuss your legal rights, call Bragar Eagel and Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

GlobeNewsWire·19h ago

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role

Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourages Investors Who Suffered Losses In GRAIL (GRAL) To Contact Him Directly To Discuss Their Options

The Motley Fool·5 days ago

Prediction: Grail Stock Will Skyrocket to $100 in 1 Year

Grail's stock has dropped more than 40% from its all-time high. It suffered a big setback, but it still has plenty of irons in the fire.

Peers Comparison

Key metrics vs top competitors for GRAIL, Inc. (GRAL)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
GRALGRAIL, Inc.Current	$68.79	$2.82B	-6.19	17.18%	-277.47%	-16.07%	—
EXASExact Sciences Corporation	$104.91	$20.02B	-95.37	17.69%	-6.4%	-8.66%	—
ILMNIllumina, Inc.	$191.76	$29.13B	35.19	-0.78%	19.43%	32.84%	—
GHGuardant Health, Inc.	$162.92	$21.6B	-49.07	32.88%	-40.1%	—	—
NTRANatera, Inc.	$281.27	$40.28B	-185.05	35.9%	-9.05%	-15.13%	—
FDMT4D Molecular Therapeutics, Inc.	$12.82	$670.16M	-5.30	230194.59%	-182.34%	-36.83%	—

Compare GRAL vs Peers

GRAIL, Inc. (GRAL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXAS

Most directly comparable listed peer for GRAL.

Scale Benchmark

vs TMO

Larger-name benchmark to compare GRAL against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXAS, ILMN, GH, NTRA

GRAL SEC Filings & Documents

GRAIL, Inc. (GRAL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Feb 19, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Mar 12, 2026·SEC

FY 2025

Mar 5, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 7, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 13, 2025·SEC

Get notified when GRAL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

GRAL Frequently Asked Questions

GRAIL, Inc. (GRAL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is GRAIL, Inc.'s revenue?

GRAIL, Inc. (GRAL) reported $156.1M in revenue for fiscal year 2025.

How fast is GRAIL, Inc. growing?

GRAIL, Inc. (GRAL) grew revenue by 17.2% over the past year. This is strong growth.

Is GRAL profitable?

GRAIL, Inc. (GRAL) reported a net loss of $395.3M for fiscal year 2025.

Dividend & Returns

What is GRAL's return on equity?

GRAIL, Inc. (GRAL) has a return on equity (ROE) of -16.1%. Negative ROE indicates the company is unprofitable.

What is GRAIL, Inc.'s free cash flow?

GRAIL, Inc. (GRAL) had negative free cash flow of $291.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in GRAL back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 5, 2026

$2.29vs $2.76+17.1%

$41Mvs $39M+4.2%

Q1 2026

Feb 19, 2026

$2.44vs $3.33+26.7%

$44Mvs $44M+0.0%

Q4 2025

Nov 12, 2025

$2.46vs $3.36+26.8%

$36Mvs $35M+4.6%

Q3 2025

Aug 12, 2025

$3.18vs $3.14-1.3%

$36Mvs $34M+4.2%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

GRALGRAIL, Inc.Current

$68.79

$2.82B

-6.19

17.18%

-277.47%

-16.07%

—

EXASExact Sciences Corporation

$104.91

$20.02B

-95.37

17.69%

-6.4%

-8.66%

—

ILMNIllumina, Inc.

$191.76

$29.13B

35.19

-0.78%

19.43%

32.84%

—

GHGuardant Health, Inc.

$162.92

$21.6B

-49.07

32.88%

-40.1%

—

NTRANatera, Inc.

$281.27

$40.28B

-185.05

35.9%

-9.05%

-15.13%

—

FDMT4D Molecular Therapeutics, Inc.

$12.82

$670.16M

-5.30

230194.59%

-182.34%

-36.83%

—